Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM <b>Ⅱ</b>A to <b>Ⅲ</b>C stage breast cancer: a meta-analysis _Chinese Journal of Evidence-Based Medicine

Authors：

LIU Aijun , LU Liqing ,  ZHANG Jianping

College of Pharmacy, Jinan University, Guangzhou, 510632, P.R.China;

Corresponding?author：

ZHANG Jianping, Email: tzhangjp@jnu.edu.cn

Keywords：

Breast cancer; Neoadjuvant chemotherapy; TE regimen; CEF regimen; Chinese women; Randomized controlled trial; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.201703123

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the efficacy and safety of TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Methods Databases including PubMed, EMbase, VIP, CNKI, WanFang Data and CBM were electronically searched from inception to December 2016 to collect randomized controlled trials (RCT) on TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 14 RCTs were included. The results of meta-analysis showed that: the complete remission rate (CR) (RR=1.73, 95%CI 1.35 to 2.22, P<0.000 1) and clinical efficacy rate (RR) (RR=1.31, 95%CI 1.22 to 1.42,P<0.000 01) of the TE group were superior to those of the CEF group. But there were no significant differences between two groups in cardiac toxicity, myelosuppression and gastrointestinal reactions. Conclusions TE regimen is superior to CEF regimen in terms of efficacy for the Chinese women with ⅡA to ⅢC stage breast cancer, and there is no difference between the incidence of adverse reactions. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.

Citation： LIU Aijun, LU Liqing, ZHANG Jianping. Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM ⅡA to ⅢC stage breast cancer: a meta-analysis . Chinese Journal of Evidence-Based Medicine, 2017, 17(12): 1413-1418. doi: 10.7507/1672-2531.201703123 Copy

1.	Frei E. Clinical cancer research: an embattled species. Cancer, 1982, 50(10): 1929-1992.
2.	唐利立, 張超杰, 劉少華, 等. 新輔助化療對Ⅱ期和Ⅲ期乳腺癌的療效觀察. 中國腫瘤臨床, 2005, 32(22): 1293-1295.
3.	滿莉, 周立中, 董禹洋. 兩種新輔助化療方案治療進展期乳腺癌的療效對比研究. 中國腫瘤臨床與康復, 2014, 21(3): 276-279.
4.	范揚航, 吳智勇, 黃建豪, 等. 多西他賽聯合表柔比星新輔助化療治療局部晚期乳腺癌療效觀察. 廣東醫學, 2011, 32(8): 1059-1061.
5.	李冬云, 黃昌杰, 湛永滋, 等. 乳腺癌兩種新輔助化療方案的臨床觀察(附64例報告). 廣西醫學, 2012, 34 (9): 1215-1216.
6.	柴小郁. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 基層醫學論壇, 2014,18(29): 3960-3961.
7.	聶紅霞, 劉葉娟, 唐偉敬. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 當代醫學, 2013, 19(5): 48-49.
8.	張莉. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 中外醫學研究, 2014, 12(2): 116-117.
9.	陳麗娟. 新輔助化療方案TE與FEC治療局部晚期乳腺癌療效觀察. 中國醫藥指南, 2011, 9(28): 214-216.
10.	鄒玉峰. 局部晚期乳腺癌新輔助化療的研究. 中國當代醫藥, 2016, 23(32): 65-67.
11.	鄭慧. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療治療中的療效評價. 中國實用醫藥, 2014, 9(21): 111-112.
12.	劉一范. 表阿霉素聯合紫杉醇新輔助化療治療局部晚期乳腺癌療效分析. 臨床合理用藥雜志, 2014, 7(19): 60-61.
13.	劉宏軍, 楊德啟, 曹迎明, 等. 不同新輔助化療方案治療乳腺癌的臨床觀察. 中國腫瘤臨床, 2004, 31 (16): 31-34.
14.	賈琦. 兩種新輔助化療方案治療乳腺癌的近期療效和不良反應比較. 哈爾濱醫藥, 2012, 32(3): 196-197.
15.	王冰濤, 馬向濤, 姚金華, 等. 術前ET與CEF新輔助化療方案治療乳腺癌的臨床觀察. 北京醫學, 2007, 29(11): 658-660.
16.	韓瑜. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療治療中的臨床療效分析. 中國傷殘醫學, 2013, 21(9): 162-163.
17.	Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 2005, 16(10): 1569-1583.
18.	陳燦銘, 沈坤煒, 吳炅, 等. 去甲長春花堿加表柔比星新輔助化療方案治療局部晚期乳腺癌的臨床研究. 中國癌癥雜志, 2003, 13(4): 28-31.
19.	Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical. Oncologist, 2004, 9(Suppl 2): 24-32.
20.	Andrade JM, Carrara HH , Pimentel FF, et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Med Oncol, 2011, 28(Suppl 1): 65-69.
21.	De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 2008, 26(1): 44-53.
22.	武陽. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療中的應用觀察. 中國實用醫藥, 2014, 9(24): 155-156.

1. Frei E. Clinical cancer research: an embattled species. Cancer, 1982, 50(10): 1929-1992.
2. 唐利立, 張超杰, 劉少華, 等. 新輔助化療對Ⅱ期和Ⅲ期乳腺癌的療效觀察. 中國腫瘤臨床, 2005, 32(22): 1293-1295.
3. 滿莉, 周立中, 董禹洋. 兩種新輔助化療方案治療進展期乳腺癌的療效對比研究. 中國腫瘤臨床與康復, 2014, 21(3): 276-279.
4. 范揚航, 吳智勇, 黃建豪, 等. 多西他賽聯合表柔比星新輔助化療治療局部晚期乳腺癌療效觀察. 廣東醫學, 2011, 32(8): 1059-1061.
5. 李冬云, 黃昌杰, 湛永滋, 等. 乳腺癌兩種新輔助化療方案的臨床觀察(附64例報告). 廣西醫學, 2012, 34 (9): 1215-1216.
6. 柴小郁. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 基層醫學論壇, 2014,18(29): 3960-3961.
7. 聶紅霞, 劉葉娟, 唐偉敬. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 當代醫學, 2013, 19(5): 48-49.
8. 張莉. 新輔助化療方案在乳腺癌治療中的應用效果觀察. 中外醫學研究, 2014, 12(2): 116-117.
9. 陳麗娟. 新輔助化療方案TE與FEC治療局部晚期乳腺癌療效觀察. 中國醫藥指南, 2011, 9(28): 214-216.
10. 鄒玉峰. 局部晚期乳腺癌新輔助化療的研究. 中國當代醫藥, 2016, 23(32): 65-67.
11. 鄭慧. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療治療中的療效評價. 中國實用醫藥, 2014, 9(21): 111-112.
12. 劉一范. 表阿霉素聯合紫杉醇新輔助化療治療局部晚期乳腺癌療效分析. 臨床合理用藥雜志, 2014, 7(19): 60-61.
13. 劉宏軍, 楊德啟, 曹迎明, 等. 不同新輔助化療方案治療乳腺癌的臨床觀察. 中國腫瘤臨床, 2004, 31 (16): 31-34.
14. 賈琦. 兩種新輔助化療方案治療乳腺癌的近期療效和不良反應比較. 哈爾濱醫藥, 2012, 32(3): 196-197.
15. 王冰濤, 馬向濤, 姚金華, 等. 術前ET與CEF新輔助化療方案治療乳腺癌的臨床觀察. 北京醫學, 2007, 29(11): 658-660.
16. 韓瑜. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療治療中的臨床療效分析. 中國傷殘醫學, 2013, 21(9): 162-163.
17. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 2005, 16(10): 1569-1583.
18. 陳燦銘, 沈坤煒, 吳炅, 等. 去甲長春花堿加表柔比星新輔助化療方案治療局部晚期乳腺癌的臨床研究. 中國癌癥雜志, 2003, 13(4): 28-31.
19. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical. Oncologist, 2004, 9(Suppl 2): 24-32.
20. Andrade JM, Carrara HH , Pimentel FF, et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Med Oncol, 2011, 28(Suppl 1): 65-69.
21. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 2008, 26(1): 44-53.
22. 武陽. 表阿霉素聯合紫杉醇在局部晚期乳腺癌新輔助化療中的應用觀察. 中國實用醫藥, 2014, 9(24): 155-156.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM ⅡA to ⅢC stage breast cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content